https://www.selleckchem.com/products/en450.html
In conclusion, we were able to determine that the bacterial interactions are not always positive or synergistic, but they also might be neutral or antagonistic. To compare direct costs and treatment utility associated with the second-line therapy with rituximab and tumour necrosis factor inhibitors (TNFis) (adalimumab, etanercept, and infliximab) in patients with Rheumatoid Arthritis (RA) using data from a prospective registry. Health Assessment Questionnaire Disability Index (HAQ-DI) scores and RA-related healthcare resource utilization
Like
Comment
Share
